Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

…, SI Sherman, J Krajewska, CC Lin, F Vaisman… - The Lancet …, 2021 - thelancet.com
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously
treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have …

Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy

F Vaisman, D Momesso, DA Bulzico… - Clinical …, 2012 - Wiley Online Library
Objective To validate the A merican T hyroid A ssociation ( ATA ) initial risk of recurrence
scheme and the M emorial S loan K ettering C ancer C enter ( MSKCC ) response to therapy re‐…

Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease …

F Vaisman, A Shaha, S Fish… - Clinical …, 2011 - Wiley Online Library
Objective To describe the risk of structural disease recurrence in a cohort of patients with
differentiated thyroid cancer selected for treatment with either thyroid lobectomy or total …

Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine

DP Momesso, F Vaisman, SP Yang… - The Journal of …, 2016 - academic.oup.com
Context: Although response to therapy assessment is a validated tool for dynamic risk
stratification in patients with differentiated thyroid cancer (DTC) treated with total thyroidectomy (TT…

An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer

…, F Vaisman, R Corbo, D Momesso, M Vaisman… - Thyroid, 2016 - liebertpub.com
Background: Age is a critical factor in outcome for patients with well-differentiated thyroid
cancer. Currently, age 45 years is used as a cutoff in staging, although there is increasing …

Survival from differentiated thyroid cancer: what has age got to do with it?

…, F Vaisman, D Momesso, R Corbo, M Vaisman… - Thyroid, 2015 - liebertpub.com
Background: In most staging systems, 45 years of age is used to differentiate low risk thyroid
cancer from high risk thyroid cancer. However, recent studies have questioned both the …

In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete …

F Vaisman, H Tala, R Grewal, RM Tuttle - Thyroid, 2011 - liebertpub.com
Background: We previously demonstrated the clinical utility of using response to therapy
variables obtained during the first 2 years of follow-up to actively modify initial risk estimates …

[HTML][HTML] Thyroid carcinoma in children and adolescents—systematic review of the literature

F Vaisman, R Corbo, M Vaisman - Journal of Thyroid Research, 2011 - hindawi.com
Thyroid cancer in children and adolescents is usually a major concern for physicians, patients,
and parents. Controversies regarding the aggressiveness of the clinical presentation and …

[HTML][HTML] Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations

A Rangel-Pozzo, L Sisdelli, MIV Cordioli, F Vaisman… - Cancers, 2020 - mdpi.com
Simple Summary Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated
thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence …

Molecular markers involved in tumorigenesis of thyroid carcinoma: focus on aggressive histotypes

GC Penna, F Vaisman, M Vaisman… - … and genome research, 2017 - karger.com
Thyroid cancer derived from follicular cells (TCDFC) comprises well-differentiated (papillary
and follicular) carcinoma, poorly differentiated carcinoma, and anaplastic carcinoma. …